Search

everythinglearnresearchcommunity

for

Search:↓

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.

Ashwagandha is generally considered safe for hair while on Dutasteride, as its effects on testosterone are minimal and it may reduce anxiety. Some users report positive effects on hair thickness and anxiety reduction when using ashwagandha alongside finasteride.

A user found that antihistamines stop their hair loss and related symptoms, but they experience side effects like sedation and chest pain. They are seeking alternative solutions or topical antihistamines to avoid systemic side effects.

Azelaic acid is considered a strong DHT inhibitor with no reported sexual side effects, making it a potential alternative for those who cannot use finasteride. It can be used with minoxidil, but may cause skin irritation.

Finasteride may cause insomnia, and ashwagandha is suggested to help with sleep issues without significantly affecting testosterone or DHT levels. Users discuss personal experiences with sleep disturbances and suggest consulting a doctor if side effects persist.

The conversation discusses the potential of topical cetirizine (Zyrtec) for hair growth in comparison to minoxidil, noting cetirizine's ability to reduce prostaglandin D2, which inhibits hair growth. Users share mixed experiences with cetirizine for allergies and scalp health, and there's a mention of the risk of dementia with long-term antihistamine use.

Azelaic acid is discussed as a DHT inhibitor with no reported sexual side effects, but its effectiveness and absorption as a topical treatment are questioned. The user is interested in azelaic acid due to concerns about finasteride affecting penile health.

The conversation discusses whether to use finasteride for hair loss, considering its role in inhibiting DHT and 5AR, which can affect brain function and mood. Some users report anxiety and depression from finasteride, while others do not experience these side effects and emphasize the importance of DHT for brain and prostate health.

The user switched from topical to oral minoxidil (5mg daily) a year ago, saw no improvement, and experienced chest pain and trouble sleeping after stopping. They are considering whether to resume and taper the dosage due to stress and anxiety.

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

Clascoterone (Breezula) showed positive results for treating hair loss without affecting cortisol levels. Opinions vary, with some users optimistic about its potential and others critical of its effectiveness compared to existing treatments like finasteride.

A user experienced severe depression and anxiety after taking finasteride for hair loss, which resolved after stopping the medication. They shared their story to warn others about potential side effects.

A user experienced hair loss and texture changes, tried minoxidil and finasteride, and considered antihistamines like Cetirizine for potential histamine issues. They reported improved alertness but continued shedding.

The conversation is about someone switching from Minoxidil and Finasteride to Redensyl, Procapil, and Capixyl serums due to anxiety over potential side effects, and they are inquiring about others' regrowth experiences with these serums. Some doctors in India have prescribed these serums, and the person knows others who are satisfied with the results.

The conversation discusses transitioning from topical to oral minoxidil for hair loss treatment and explores the potential use of Aminexil, despite concerns about its effectiveness compared to minoxidil. It highlights the risks and side effects of oral minoxidil, such as potential heart and liver damage, and emphasizes the importance of monitoring blood pressure.

A 20-year-old with anxiety and depression is considering finasteride for hair loss but is worried about potential side effects. They decide to consult a doctor and consider starting with a low dose, while also exploring topical finasteride as a potentially safer option.

A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

A 19-year-old is stressed about applying minoxidil due to OCD and anxiety. Another user suggests switching to oral minoxidil to reduce stress.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.

The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.